Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

Clinical trial NCT06492850 · UNKNOWN

Trial details

NCT number: NCT06492850
Sponsor: Frontera Therapeutics
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

X-Linked Retinitis Pigmentosa (XLRP)

Start date: 2024-04-01
Primary completion: 2025-08-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.